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Abstract
Background: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma
(HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib
remains largely unknown. Previous studies have shown that fibroblast growth factor 19 (FGF19) expression correlates
with tumor progression and poor prognosis of HCC. Here, we demonstrate the novel role of FGF19 in HCC resistance
to sorafenib therapy.
Methods: FGF19 Knockdown cells were achieved by lentiviral-mediated interference, and FGFR4 knockout cells were
achieved by CRISPR-Cas9. Protein levels of FGF19, FGFR4 and c-PARP in various HCC cell lines were measured by Western
blotting analysis. Cell viability was determined by MTS assay, apoptosis was determined by DAPI nuclear staining and
Western blot of c-PRAP, and ROS generation was determined by DCFH-DA staining and electrochemical biosensor.
Results: We showed that FGF19, when overexpressed, inhibited the effect of sorafenib on ROS generation and apoptosis
in HCC. In contrast, loss of FGF19 or its receptor FGFR4 led to a remarkable increase in sorafenib-induced ROS generation
and apoptosis. In addition, knockdown of FGF19 in sorafenib-resistant HCC cells significantly enhanced the sensitivity to
sorafenib. Importantly, targeting FGF19/FGFR4 axis by ponatinib, a third-generation inhibitor of chronic myeloid leukemia,
overcomes HCC resistance of sorafenib by enhancing ROS-associated apoptosis in sorafenib-treated HCC.
Conclusion: Our results provide the first evidence that inhibition of FGF19/FGFR4 signaling significantly overcomes
sorafenib resistance in HCC. Co-treatment of ponatinib and sorafinib may represent an effective therapeutic approach for
eradicating HCC.
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Background
Hepatocellular carcinoma (HCC) is the sixth common
malignancies worldwide and the third leading cause of
cancer-associated mortality [1–5]. Although advances in
diagnostic techniques and instrumentation of oncology
have improved the early diagnosis of HCC, the median
survival of patients with this disease is still low. Recently,
a number of molecular targeted drugs have been illus-
trated to be promising agents in prolonging the overall
survival of patients with advanced HCC. Particularly, as
a multikinase inhibitor of Raf/MEK/ERK signaling and
the receptor tyrosine kinases (RTKs), sorafenib leads to
a survival benefit for patients through reducing tumor
angiogenesis and increasing cancer cell apoptosis [6–9].
However, its use is often hampered by the occurrence of
drug resistance [10–12]. Urgently needed to resolve the
problem is to explore the mechanisms of resistance on
sorafenib and seek an effective systemic therapy for pa-
tients after failure of sorafenib treatment.
FGF19 is a metabolic regulator gene belonging to the
hormone-like FGF family of signal molecules, and has ac-
tivity as an ileum-derived postprandial hormone [13, 14].
Genomic and functional analyses show that FGF19 acts as
an oncogenic driver in HCC [15–17]. FGFR4 is the pre-
dominant FGFR isoform in FGFRs in human hepatocytes
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and both FGF19 and FGFR4 are highly expressed in pri-
mary HCC [18]. FGF19 has unique specificity for FGFR4
[19], and through binding to it, FGF19 activates different
intracellular pathways, including GSK3β/β-catenin/E-cad-
herin signaling [20]. Emerging studies indicate a focal,
high-level amplification frequency of FGF19 in HCC clin-
ical samples, which is positively correlated with tumor size,
pathological stage and poor prognosis [15, 21–23]. Re-
cently, HCC responder cases to sorafenib were collected
to explore the association between the efficacy of sorafenib
and gene alterations [24]. Using next generation sequen-
cing and copy number assay, an FGF19 copy number gain
was detected more frequently among complete response
cases than among non-complete response cases, suggest-
ing FGF19 amplification may be a predictor of a response
to sorafenib [24]. Therefore, increased understanding of
the clinical relevance of FGF19 may bring molecular in-
sights into the pathogenesis and treatment of HCC.
In this work, we determined the importance of FGF19
in sorafenib-induced cell viability, apoptosis, and accu-
mulation of mitochondrial reactive oxidative species
(ROS). We also evaluated the role of FGF19 and FGF19/
FGFR4 axis in sorafenib resistance, and determined the
synergistic effect of sorafenib and FGFR inhibitor ponati-
nib on sorafenib-resistant HCC cells. Our data reveal
that FGF19 is essential for sorafenib efficacy and resist-
ance in the treatment of HCC. This study provides crit-
ical rationale to test the inhibition of FGF19 signaling in
patients with sorafenib-resistant HCC.
Methods
Cell lines, reagents and standard assays
HCC cell lines (MHCC97L, MHCC97H, HepG2, and
SMMC7721) were directly obtained from American Type
Culture Collection (ATCC, Rockville, MD). Sorafenib and
ponatinib were purchased from Selleckchem (Houston,
TX, USA). Superoxide dismutase (SOD), DMSO and DAPI
were purchased from Sigma-Aldrich (St. Louis, MO).
Standard cell culture, transient transfections, lentiviral
transduction, quantitative RT-PCR (qRT-PCR), western
blot, and cell viability assays were carried out as described
previously [20].
Antibodies and constructs
Antibodies raised against FGF19 and FGFR4 were pur-
chased from Abcam (Cambridge, MA), β-actin was from
Sigma-Aldrich (St Louis, MO), and cleaved PAPR (c-PARP)
was from Cell Signaling (Beverly, MA). The full-length of
human FGF19 and FGFR4 cDNA were cloned into
pcDNA3.1(+) expression vector (Life technologies,
Carlsbad, CA). Lentiviral vectors harboring shRNAs
targeting FGF19 were obtained from GeneCopoeia
(Rockville, MD). LentiCRISPR v2 vector used for gener-
ating CRISPR-Cas9 targeted deletion of FGFR4 was
obtained from Feng Zhang (Addgene plasmid #52961).
All the plasmids used in this study were verified by
sequencing.
Development of sorafenib resistant cells
To generate sorafenib-resistant cells, cells were treated
with LC50 of sorafenib and the concentration was grad-
ually increased by 10% every 2 weeks until the maximum
tolerated doses (10 μM) have been reached. Sorafenib-
resistant cells were continuously cultured in the pres-
ence of 1 μM of sorafenib.
Electrochemical detection of O2
•-
Electrochemical detection of superoxide (O2
•-) released
from cells was established as previously described [25]. In
brief, 5 × 105 cells were incubated with sorafenib or/and
other regents as indicated. A cyclic voltammetry (CV) was
used to monitor cellular O2
•- generation on CHI760E elec-
trochemical station (ChenHua Instruments, Wuhan,
China). SOD was added to the medium to verify the
current changes was caused by O2
•-. The electrochemical
sensors were calibrated at different concentrations of O2
•-
in a fluidic chamber, and percentages of peak (potential =
0.7 V; current enhancement) were compared and calcu-
lated against the control curve and evaluated the release of
the analysts.
Fluorescence analysis of intracellular oxidative stress
To further validate the generation of O2
•-, intracellular
ROS were also determined by the oxidant-sensing fluor-
escent probe 2′,7′-dichlorodihydrofluorescein diacetate
(DCFH-DA, Sigma-Aldrich). Briefly, cells were incu-
bated with 10 μM of DCFH-DA for 20 min at 37 °C,
after which they were washed, trypsinized, resuspended
and immediately analyzed for fluorescence intensity
under a fluorescence microscope (IX-71, Olympus Corp.,
Tokyo, Japan). Median fluorescence intensity was quan-
tified by the NIH ImageJ software.
Determination of apoptotic bodies by DAPI nuclear
staining
The presence of apoptotic bodies and nuclei morphology
were determined by DAPI staining. Briefly, cells were
fixed in 4% paraformaldehyde-PBS solution for 10 min
and were stained with DAPI (300 nM) for 30 min at
room temperature. Cells were examined for apoptotic
bodies and nuclear morphology and photographed under
fluorescence microscopy. Apoptotic cells were recog-
nized and determined based on characteristic observa-
tions including the presence of fragmented, condensed,
and degraded nuclei.
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Statistical analysis
The data were presented as means ± SD from three or
more independent experiments and were analyzed by
the Student’s t-test at a significance level of P < 0.05.
Results
Sorafenib induces ROS-associated apoptosis in HCC cells
To determine the effective dose range of sorafenib in hu-
man HCC cells, four cell lines (MHCC97L, MHCC97H,
HepG2 and SMCC7721) were selected and treated with
varied doses of sorafenib. The average LI50 (Lethal Con-
centration 50%) in MHCC97L, MHCC97H and
SMCC7721 cells is ~4 μM, while HepG2 cells have LC50
value of 6 μM (Fig. 1a). We used the LC50 dosages to treat
different HCC cell lines and determined the effect of so-
rafenib on apoptosis. Results from DAPI staining showed
that sorafenib induced ~16, 40 and 52% apoptotic cells in
MHCC97L cells at 8, 12, 24 h after treatment, respectively
(Fig. 1b and Additional file 1: Figure S1A). The similar
apoptotic response was observed in other three cell lines
(Fig. 1b and Additional file 1: Figure S1A).
ROS and the resulting oxidative stress play a pivotal role
in apoptosis [26, 27]. We thus investigated the relationship
between sorafenib-induced apoptosis and oxidative stress.
ROS production was evaluated by DCFH-DA, showing a
significant increase of fluorescence in the cells exposed to
sorafenib (Fig. 1c and Additional file 1: Figure S1B). These
observations suggest that sorafenib-induced oxidative
stress may lead to HCC cell apoptosis. To study whether
the oxidative stress induced by sorafenib was mediated via
O2
•−, we monitored O2
•− release by the well-established
electrochemical biosensors (Additional file 2: Figure S2).
The amount of O2
•− generation (a 25% increase compared
with the controls) in all examined cell lines reached max-
imum at 8 h after sorafenib treatment and then decreased
in the following treatment (Fig. 1d), which was consistent
Fig. 1 Sorafenib induces apoptosis and ROS generation in HCC cells. a The effect of sorafenib (Sora) on cell viability. The HCC cell lines
(MHCC97L, MHCC97H, HepG2 and SMCC-7721) were treated with indicated concentrations of Sora for 24 h, and cell viability was determined
by MTS assays as previously described. b–d The effect of Sora on cell apoptosis and ROS generation. The HCC cell lines were treated with Sora
(4 μM for MHCC97L, MHCC97H and SMCC-7721, and 6 μM for HepG2) over a series of time points. Apoptosis was determined by DAPI staining
(b); ROS generation was determined by DCFH-DA staining (c); and O2
•− generation was determined by electrochemical biosensor (d). SOD:
superoxide dismutase. * p < 0.05; ** p < 0.01
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with the trend of ROS generation in presence of sorafenib
(Fig. 1c). These data suggest that elevated intracellular O2
•−
levels contribute to sorafenib-induced oxidative stress.
FGF19 is a critical regulator involved in HCC cell response
to sorafenib
To investigate the impact of FGF19 on sorafenib-
induced HCC cell apoptosis and ROS generation, we
manipulated FGF19 expression levels in different HCC
cell lines. Cell viability assays showed that FGF19 over-
expression in MHCC97L cells prevented cell death
against sorafenib (Fig. 2a). Increased apoptotic cells and
cleaved PARP were also seen in the sorafenib treatment,
which were attenuated when FGF19 was overexpressed
(Fig. 2b and c). Moreover, forced expression of FGF19
abolished sorafenib-induced production of ROS and O2
•−
(Fig. 2d and e).
We next examined the effects of FGF19 knockdown on
sorafenib-induced cell phenotypes. As expected, depletion
of FGF19 in MHCC97H cells significantly decreased sur-
vival cells exposed to sorafenib (Fig. 3a). FGF19 knock-
down also enhanced apoptotic rate in the treatment of
sorafenib (Fig. 3b and c), showing increased cells with
apoptotic nuclei and increased cleaved PARP levels. In
contrast to the phenotypes observed in FGF19 overex-
pressing cells, loss of FGF19 expression enhanced ROS
generation and O2
•− release when compared with the
knockdown control cells (Fig. 3d and e). Collectively, these
Fig. 2 FGF19 overexpression protects HCC cells against sorafenib. a–e The effect of FGF19 overexpression on Sora-induced HCC cell apoptosis and
ROS generation. MHCC97L cells expressing pcDNA3.1-FGF19 (FGF19 O/E) or empty vector (EV) were treated with 4 μM of Sora over a series of time
points before analysis. Cell viability was determined by MTS assays (a); cell apoptosis was determined by DAPI staining (b) and Western blot of cleaved
PARP (c-PARP) (c); ROS generation was determined by DCFH-DA staining (d); and O2
•− generation was determined by electrochemical bio-
sensor (e). In (c), expression levels were normalized against actin and reported relative to controls (fold changes shown below each lane).
* p < 0.05; ** p < 0.01
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observations demonstrate FGF19 is deeply involved in
sorafenib-induced cell response.
FGFR4 is essential for ROS-associated apoptosis by
sorafenib
FGF19 drives cell proliferation and migration through
interacting with its cognate receptor FGFR4 [28], which
promoted us to investigate the importance of FGFR4 in
sorafenib-induced cell apoptosis. Similar to loss of
FGF19 expression (Fig. 3), FGFR4 knockout by CRISPR-
Cas9 system decreased cell survival of MHCC97H in re-
sponse to sorafenib (Fig. 4a), and enhanced cell apop-
tosis by sorafenib accompanying increased generation of
ROS and O2
•− (Fig. 4b–e). Interestingly, overexpression
of FGFR4 in MHCC97L cells did not produce any effect
on cell viability, apoptosis and ROS release when ex-
posed to sorafenib (Additional file 3: Figure S3). These
data demonstrate that the role of FGFR4 in sorafenib is
largely dependent on FGF19 status, suggesting FGF19/
FGFR4 axis plays an essential part in the resistance of
HCC cells to sorafenib.
Loss of FGF19 in sorafenib-resistant HCC cells increases
the sensitivity to sorafenib
To study the mechanism of sorafenib resistance, we gen-
erated sorafenib-resistant HCC cells. MHCC97H cells
displayed a spindle-shaped appearance, whereas these
cells experiencing long-term administration of sorafenib ex-
hibited an epithelial-like morphology (Additional file 4: Fig-
ure S4A). These resistant cells significantly enhanced cell
Fig. 3 Loss of FGF19 expression enhances sorafenib-induced apoptosis associated with ROS. a–e The effect of FGF19 depletion on Sora-induced
HCC cell apoptosis and ROS generation. MHCC97H cells expressing FGF19 shRNA (shFGF19) or control shRNA (shNC) were treated with 4 μM of
Sora over a series of time points before analysis. Cell viability was determined by MTS assays (a); apoptosis was determined by DAPI staining (b)
and Western blot of c-PRAP (c); ROS generation was determined by DCFH-DA staining (d); and O2
•− generation was determined by electrochemical
biosensor (e). In c, expression levels were normalized against actin and reported relative to controls (fold changes shown below each lane).
* p < 0.05; ** p < 0.01
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viability, and reduced ROS-associated cell apoptosis ex-
posed to high doses of sorafenib (Additional file 4: Figure
S4B–S4F). However, the FGF19 levels didn’t change in so-
rafenib-resistant cells compared with wildtype cells
(Additional file 4: Figure S4C), indicating that sorafenib
does not affect FGF19 expression levels.
We next determined the consequences of FGF19 deple-
tion in the sorafenib-resistant cells exposed to high dose of
sorafenib (20 μM) (Fig. 5 and Additional file 5: Figure S5).
In sorafenib-resistant MHCC97H cells, knockdown of
FGF19 (Fig. 5a) significantly enhanced the sensitivity to so-
rafenib, showing a decrease in cell viability (Fig. 5b) and an
increase in ROS-associated cell apoptosis (Fig. 5c-e). The
same phenotypes were observed in sorafenib-resistant
HepG2 cells where FGF19 was depleted (Additional file 5:
Figure S5). Taken together, our findings underlie the im-
portance of FGF19 in sorafenib resistance and suggest that
inactivation of FGF19 may have a potential therapeutic
value in sorafenib treatment.
Ponatinib facilitates sorafenib-resistant HCC cells to death
Our previous study have shown that ponatinib can ef-
fectively block FGF19/FGFR4 axis in HCC cells through
suppression of FGFR4 activity [20]. We thus investigated
the efficacy of ponatinib in sorafenib resistance. Treat-
ment of sorafenib-resistant MHCC97H cells with 10 μM
of ponatinib led to a 20% reduction in cell viability
(Fig. 6a). Intriguingly, co-treatment of ponatinib (10 μM)
and high dose of sorafenib (20 μM) showed a 60% de-
creased cell viability (Fig. 6a), suggesting that the synergistic
Fig. 4 Knockdown of FGFR4 promotes ROS-associated HCC cell apoptosis by sorafenib. a–e The effect of FGFR4 knockout on Sora-induced HCC
cell apoptosis and ROS generation. FGFR4 knockout MHCC97L cells by CRISPR sgRNA targeting exonic regions (FGFR4 KO) were treated with
4 μM of Sora over a series of time points before analysis. Cell viability was determined by MTS assays (a); Apoptosis was determined by DAPI
staining (b) and Western blot of c-PARP (c); ROS generation was determined by DCFH-DA staining (d); and O2
•− generation was determined by
electrochemical biosensor (e). In c, expression levels were normalized against actin and reported relative to controls (fold changes shown below
each lane). * p < 0.05; ** p < 0.01
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effect of these two drugs is much greater than each drug
given alone. Moreover, ponatinib facilitated sorafenib-
resistant HCC cells to death which was associated with in-
creased ROS, and co-treated with sorafenib enhanced these
phenotypes (Fig. 6b–e). These data suggest that adjunct
ponatinib could have additive anti-cancer effects when used
with sorafenib in patients with HCC.
Discussion
HCC is increasing in incidence with high fatality rate, and
new therapies are urgently required to treat this disease.
As first-line systemic therapy exists for patients with ad-
vanced HCC, sorafenib prolonged median survival and the
time to progression of patients nearly 3 months [29, 30].
By dually targeting MAPK signaling and the activation of
RTKs, sorafenib inhibits cell proliferation and induces cell
apoptosis in HCC. However, the addiction switches and
compensatory pathways are activated simultaneously or se-
quentially in the treatment of sorafenib, which may due to
high molecular heterogeneity in HCC [31, 32]. Therefore,
seeking novel anti-cancer agents or evaluating sorafenib in
combination with other molecular targeted treatment is
largely needed. A recent clinical report demonstrate that a
copy number gain of FGF19 in HCC may represent a pre-
dictive biomarker for primary resistance to sorafenib [24].
In the present work, we provide new insights into the mo-
lecular basis of sorafenib resistance with the FGF19 in-
volvement, and indicate that therapeutic strategies such as
combining sorafenib with ponatinib can act synergistically
to overcome the acquired resistance to sorafenib and im-
prove anti-cancer effects in HCC.
ROS-sensitive signaling pathways are persistently ele-
vated in many cancer types, where they participate in
cell growth/survival, oxidative damage and metabolism
[33, 34]. The half-period of free radical is only few seconds,
therefore, detection of the short lifetime of free radicals
particularly demands fast response of the analytical tool to
the changes in concentration to obtain sufficient signal-to-
noise ratios [35]. Electrochemical biosensors have become
promising candidates for in situ analysis of free radicals
[36]. We have successfully performed electrochemical bio-
sensors to determine the intracellular oxidative balance in
Fig. 5 FGF19 Knockdown of in sorafenib-resistant HCC cells increases the sensitivity to sorafenib. (a) The knockdown effect of FGF19 in Sora-resistant
MHCC97H (MHCC97H Sora-R) cells. (b-e) The effect of FGF19 knockdown on Sora-induced apoptosis in MHCC97H Sora-R cells. FGF19 was knocked
down in MHCC97H Sora-R cells by lentiviral shRNA. FGF19 knockdown cells (shFGF19) and the control cells (shNC) were treated with different doses of
Sora for 24 hours, and cell viability was determined by MTS assays (b). FGF19 knockdown cells (shFGF19) and the control cells (shNC) were treated
with 20 μM of Sora over a series of time points before analysis. Apoptosis was determined by DAPI staining (c); ROS generation was determined by
DCFH-DA staining (d); and O2
•− generation was determined by electrochemical biosensor (e). In a, expression levels were normalized against actin and
reported relative to controls (fold changes shown below each lane). * p < 0.05; ** p < 0.01
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the PLX4032-treated melanoma cells [25]. Here, we ex-
plore that electrochemical biosensors combined with con-
ventional methods of ROS detection can be used for
monitoring extracellular and intracellular levels of oxida-
tion/reduction more precisely during drug treatment.
Disproportional increase in intracellular ROS can in-
duce cancer cell apoptosis [37], which can be achieved
with sorafenib shown in this study, suggesting that
sorafenib-induced high levels of ROS may turn on proa-
poptotic signaling. Recent studies indicate that FGF19/
FGFR4 axis is a key signaling in certain forms of HCC
[38, 39]. Interestingly, either knockdown of FGF19 or
FGFR4 or treated with ponatinib enhances ROS levels
and apoptosis in sorafenib-resistant HCC cells. These
observations indicate that FGF19/FGFR4 axis also con-
tributes to HCC resistance to sorafenib.
In our previous work, we have provided evidence that
FGF19 secreted from either HCC cells or tumor micro-
environment can activate its specific receptor FGFR4 on
the surface of HCC cells [20]. We show here that the ef-
fects of sorafenib resistance can be overcome, at least par-
tially, through blocking FGF19/FGFR4 signaling. Using the
third-generation tyrosine-kinase inhibitor ponatinib, we
found it was able to suppress almost all FGF19 activities
through the inhibitory efficacy in FGFR4. We also show
that in combination with the treatment of sorafenib, pona-
tinib plays a role in reversing the phenotypes induced by
sorafenib resistance, such as reduced cell viability and en-
hanced cell apoptosis. These findings suggest the potential
therapeutic effect of FGF19/FGFR4 blockade in patients
with HCC, and demonstrate that the combination of pona-
tinib and sorafenib is more potent than either drug alone.
Knockdown of FGF19 leads to decreased cell prolifera-
tion, migration and invasion in HCC, which may also
cause alternative signaling pathways that are either up-
or down- regulated. Therefore, investigation of the over-
all gene expression profiles after FGF19 depletion will
give us insight into the precise mechanism of FGF19-
associated sorafenib resistance. Although our data are
limited to in vitro characterization of HCC cells and will
require further validation in animal models and clinical
studies, this work provides a rational basis for FGF19/
FGFR4 axis for the treatment of sorafenib-resistant
HCC, and suggests that inhibition of FGF19/FGFR4 sig-
naling may represent an attractive strategy for overcom-
ing sorafenib resistance in HCC.
Fig. 6 Ponatinib facilitates sorafenib-resistant HCC cells to death. a-e The effect of ponatinib (Pona) on Sora-induced ROS generation and apoptosis in
Sora-resistant HCC cells. Sora-resistant MHCC97H (MHCC97H Sora-R) cells were treated with 20 µM of Sora and 10 µM of Pona singly or in combination.
Cell viability was determined by MTS assays (a); apoptosis was determined by DAPI staining (b) and Western blot (c); ROS generation was determined
by DCFH-DA staining (d); and O2•− generation was determined by electrochemical biosensor (e). In c, expression levels were normalized against actin
and reported relative to controls (fold changes shown below each lane). * p<0.05; ** p<0.01
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Conclusions
In summary, this work demonstrates that elevated FGF19
expression or hyperactivation of FGF19/FGFR4 signaling
in HCC cells is one of the main mechanisms of sorafenib
resistance, and blocking FGF19/FGFR4 axis by ponatinib
can overcome the resistance of HCC cells to sorafenib
through enhancing ROS-associated apoptosis. Our studies
provide the basis for developing a novel molecularly tar-
geted therapeutics to prevent single drug resistance. In fu-
ture work, we will collect the tumor samples from
patients with sorafenib-sensitive or resistant HCC to ex-
plore clinical importance of the FGF19/FGFR4 axis.
Additional files
Additional file 1: Figure S1. Representative images of sorafenib-
induced ROS-associated cell apoptosis. HCC cell lines were treated with
Sora (4 μM for MHCC97L, MHCC97H and SMCC-7721, and 6 μM for
HepG2) over a series of time points. Apoptosis was determined by DAPI
staining (A), and ROS generation was determined by DCFH-DA staining
(B). (TIF 4418 kb)
Additional file 2: Figure S2. The structure diagram of electrochemical
biosensors with a three-electrode system. (TIF 355 kb)
Additional file 3: Figure S3. FGFR4 overexpression does not chance
sorafenib-induced cell response. (A–E) The effect of FGFR4 overxpression on
Sora-induced HCC cell apoptosis and ROS generation. FGFR4 overexpressing
MHCC97H cells (FGFR4 O/E) were treated with 4 μM of Sora over a series of
time points before analysis. Cell viability was determined by MTS assays (A);
cell apoptosis was determined by DAPI staining (B) and Western blot (C);
ROS generation was determined by DCFH-DA staining (D); and O2
•−
generation was determined by electrochemical biosensor (E). In (C),
expression levels were normalized against actin and reported relative
to controls (fold changes shown below each lane). (TIF 1164 kb)
Additional file 4: Figure S4. Sorafenib-resistant MHCC97H cells highly
resistant to sorafenib-induced apoptosis and ROS generation. (A–F) The
effect of Sora-resistant cells on Sora-induced HCC cell apoptosis and ROS
generation. Sora-naive (WT) and Sora-resistant MHCC97H (MHCC97H
Sora-R) cells were exposed to 20 μM of Sora over a series of time
points before analysis. Morphological changes of cells were observed
under microscope (A); cell viability was determined by MTS assays (B);
apoptosis was determined by DAPI staining (C) and Western blot of c-
PARP (D); ROS generation was determined by DCFH-DA staining (E); and
O2
•− generation was determined by electrochemical biosensor (F). In C, ex-
pression levels were normalized against actin and reported relative to
controls (fold changes shown below each lane).* p < 0.05; ** p < 0.01.
Additional file 5: Figure S5. FGF19 knockdown in sorafenib-resistant
HepG2 cells enhances ROS-associated apoptosis by sorafenib. (A) The
knockdown effect of FGF19 in Sora-resistant HepG2 (HepG2 Sora-R) cells.
(B–E) The effect of FGF19 knockdown on Sora-induced apoptosis in
HepG2 Sora-R cells. FGF19 was knocked down in HepG2 Sora-R cells by
lentiviral shRNA. FGF19 knockdown cells (shFGF19) and the control cells
(shNC) were treated with different doses of Sora for 24 h. Cell viability
was determined by MTS assays (B); apoptosis was determined by DAPI
staining (C); ROS generation was determined by DCFH-DA staining (D),
and O2
•− generation was determined by electrochemical biosensor (E). In
A, expression levels were normalized against actin and reported relative
to controls (fold changes shown below each lane). * p < 0.05; ** p < 0.01.
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